SAB Biotherapeutics (NASDAQ:SABS) Stock Price Down 2.4% – Here’s What Happened

SAB Biotherapeutics, Inc. (NASDAQ:SABS) shares were down 2.4% during trading on Monday. The stock traded as low as $3.14 and last traded at $3.21. Approximately 697,891 shares traded hands during trading, an increase of 36% from the average session volume of 511,300 shares. The stock had previously closed at $3.29.

Wall Street Analyst Weigh In

SABS has been the subject of a number of recent research reports. Weiss Ratings raised SAB Biotherapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, September 17th. HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of SAB Biotherapeutics in a research report on Monday, June 15th. Leerink Partners upped their price objective on shares of SAB Biotherapeutics from $7.00 to $12.00 and gave the stock an “outperform” rating in a research report on Monday, June 15th. Chardan Capital raised their target price on shares of SAB Biotherapeutics from $14.00 to $16.00 and gave the stock a “buy” rating in a research note on Wednesday, June 17th. Finally, Wall Street Zen raised shares of SAB Biotherapeutics from a “strong sell” rating to a “sell” rating in a report on Monday, August 10th. Nine analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, SAB Biotherapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $12.00.

SAB Biotherapeutics Trading Down 2.4%

The company has a current ratio of 9.22, a quick ratio of 9.22 and a debt-to-equity ratio of 0.01. The business has a 50 day moving average price of $3.63 and a 200-day moving average price of $3.72. The firm has a market capitalization of $292.08 million, a PE ratio of -2.47 and a beta of 0.53.

SAB Biotherapeutics (NASDAQ:SABS) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.28) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.28). Analysts expect that SAB Biotherapeutics, Inc. will post -1.17 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. PNC Financial Services Group Inc. purchased a new stake in shares of SAB Biotherapeutics during the 1st quarter valued at approximately $29,000. Fifth Lane Capital LP acquired a new stake in shares of SAB Biotherapeutics during the fourth quarter valued at about $56,000. IFP Advisors Inc acquired a new stake in shares of SAB Biotherapeutics during the second quarter valued at about $151,000. Bank of America Corp DE raised its stake in shares of SAB Biotherapeutics by 424.8% in the 1st quarter. Bank of America Corp DE now owns 55,697 shares of the company’s stock valued at $213,000 after acquiring an additional 45,084 shares during the period. Finally, Kestra Advisory Services LLC lifted its holdings in shares of SAB Biotherapeutics by 434.6% in the 1st quarter. Kestra Advisory Services LLC now owns 61,741 shares of the company’s stock worth $236,000 after acquiring an additional 50,191 shares during the last quarter. Hedge funds and other institutional investors own 7.82% of the company’s stock.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a clinical-stage biopharmaceutical company developing targeted antibody-based medicines for infectious diseases and immune-mediated conditions. The company’s approach is designed to produce fully human polyclonal antibodies that can recognize and neutralize multiple targets associated with a disease.

SAB’s technology platform, known as DiversitAb, uses genetically engineered cattle that are capable of producing human antibodies. Antibodies harvested from the animals’ plasma are evaluated for potential use as therapeutics.